Therapy News and Research

RSS

Animal study suggests ibuprofen can reduce lung inflammation in elderly

New research shows that the lungs become more inflammatory with age and that ibuprofen can lower that inflammation.

3 Oct 2014

Taking NSAIDs with other drugs can increase risk of upper GI bleeding, study finds

Nonsteroidal anti-inflammatory drugs (NSAIDs) - such as ibuprofen and aspirin - increase one's risk of upper gastrointestinal bleeding. When taken in combination with other drugs, this risk is significantly higher, according to new research appearing in the October issue of Gastroenterology, the official journal of the American Gastroenterological Association.

3 Oct 2014

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

NKT Therapeutics today announced that the U.S. Food and Drug Administration has granted Fast Track designation to NKTT120, the company's lead therapeutic being developed for the treatment of sickle cell disease.

3 Oct 2014

Weekly growth hormone on course for phase III in children

A long-lasting formulation of human growth hormone appears to be as effective as standard daily treatment in paediatric patients with growth hormone deficiency, researchers reported at the European Society of Paediatric Endocrinology annual meeting in Dublin, Ireland.

2 Oct 2014

Empirical sulphonylurea therapy an option for neonatal diabetes

A report of empirical sulphonylurea therapy in neonatal diabetes prior to genetic diagnosis highlights contrasting approaches to the problem.

2 Oct 2014

Placenta-derived cells are safe for MS patients

Patients with Multiple Sclerosis (MS) were able to safely tolerate treatment with cells cultured from human placental tissue, according to a study published today in the journal Multiple Sclerosis and Related Disorders.

1 Oct 2014

Ganymed, BioNTech AG open new headquarters and research facility in Germany

BioNTech AG and Ganymed Pharmaceuticals AG, two premier German biotechology companies, announced today the joint- opening of a new approx. 10,000 square-meters (108,000 square-feet) headquarters and research facility.

1 Oct 2014

State highlights: New Calif. health laws signed; Mass. judge considers partners deal

A selection of health policy stories from California, Massachusetts, New York, the District of Columbia, Minnesota and Kansas.

1 Oct 2014

Research shows resveratrol in grapes inhibits bacteria that cause acne

Got grapes? UCLA researchers have demonstrated how resveratrol, an antioxidant derived from grapes and found in wine, works to inhibit growth of the bacteria that causes acne.

1 Oct 2014

Laser, needle acupuncture do not benefit patients with moderate to severe chronic knee pain

Among patients older than 50 years with moderate to severe chronic knee pain, neither laser nor needle acupuncture provided greater benefit on pain or function compared to sham laser acupuncture, according to a study in the October 1 issue of JAMA.

1 Oct 2014

Easy Breathe offers sleep apnea therapy device, AirSense CPAP

Easy Breathe, the fastest growing online sleep apnea shopping destination, today announced that it now offers the revolutionary AirSense CPAPs by ResMed.

30 Sep 2014

Research performed in anemic mice shows acetate stimulates the formation of red blood cells

UT Southwestern Medical Center researchers seeking novel treatments for anemia found that giving acetate, the major component of household vinegar, to anemic mice stimulated the formation of new red blood cells.

30 Sep 2014

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that a Phase 2a proof-of-concept study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids.

30 Sep 2014

Brain cancer patients can benefit from Rapamycin drug

Every day, organ transplant patients around the world take a drug called rapamycin to keep their immune systems from rejecting their new kidneys and hearts.

30 Sep 2014

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that it has expanded its clinical program to include a study designed to evaluate use of the Company's precision cancer monitoring technology in the management of lung cancer patients.

30 Sep 2014

More insurers change how they pay medical providers

Commercial insurers are moving rapidly from the old system of paying health providers for every test or procedure they do toward payments based on the value rather than volume of services, according to a report by Catalyst for Payment Reform, a business coalition focused on health care costs.

30 Sep 2014

Combination treatment prevents disease progression in patients with advanced melanoma

New data announced today has demonstrated that combinational treatment of cobimetinib with Zelboraf (vemurafenib), the first personalised medicine to extend life in the first-line setting for over 30 years, in patients with advanced melanoma (BRAFV600 mutation-positive) can prevent disease progression (progression-free survival; PFS) by 9.9 months compared to 6.2 months following treatment of vemurafenib alone.

30 Sep 2014

Synapse Biomedical completes enrollment in post-approval study of NeuRx DPS for ALS patients

Synapse Biomedical Inc. announced today it has completed the enrollment of the post-approval study of its NeuRx DPS System for ALS patients.

30 Sep 2014

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

Johnson & Johnson today announced a definitive agreement to acquire Alios BioPharma, Inc., a privately held clinical stage biopharmaceutical company focused on developing therapies for viral diseases, for approximately $1.75 billion in cash.

30 Sep 2014

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Updated data from the ongoing AURA study of AZD9291 shows encouraging, although still immature, median progression free survival of 9.6 months (95% CI 8.3 to NC) in patients with epidermal growth factor receptor mutation positive (EGFRm) T790M+ advanced non-small cell lung cancer (NSCLC) who had disease progression following treatment with an EGFR tyrosine kinase inhibitor (EGFR TKI).

30 Sep 2014

Therapy News and Research

Animal study suggests ibuprofen can reduce lung inflammation in elderly

Taking NSAIDs with other drugs can increase risk of upper GI bleeding, study finds

NKT Therapeutics' NKTT120 receives FDA Fast Track designation for treatment of sickle cell disease

Weekly growth hormone on course for phase III in children

Empirical sulphonylurea therapy an option for neonatal diabetes

Placenta-derived cells are safe for MS patients

Ganymed, BioNTech AG open new headquarters and research facility in Germany

State highlights: New Calif. health laws signed; Mass. judge considers partners deal

Research shows resveratrol in grapes inhibits bacteria that cause acne

Laser, needle acupuncture do not benefit patients with moderate to severe chronic knee pain

Easy Breathe offers sleep apnea therapy device, AirSense CPAP

Research performed in anemic mice shows acetate stimulates the formation of red blood cells

Sanofi, Regeneron report positive Phase 2 study of dupilumab in patients with CSwNP

Brain cancer patients can benefit from Rapamycin drug

Trovagene begins new study to assess precision cancer monitoring technology in lung cancer management

More insurers change how they pay medical providers

Combination treatment prevents disease progression in patients with advanced melanoma

Synapse Biomedical completes enrollment in post-approval study of NeuRx DPS for ALS patients

Johnson & Johnson inks definitive deal to acquire Alios BioPharma

AZD9291 shows median progression-free survival in patients with EGFRm T790M+ advanced NSCLC

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News